Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Early Results For Therapyx/Intravacc's Vaccine May Herald Progress In Gonorrhea Prevention

SBIR Award Received From The US NIAID

Executive Summary

Therapyx and Intravacc are optimizing a candidate gonorrhea vaccine following promising results in primates and the granting of a three-year SBIR award by the US NIAID.

You may also be interested in...



Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro

Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.

Double-Action Antibiotic Advances In GSK's Pipeline

GlaxoSmithKline has initiated Phase III studies, EAGLE-1 and EAGLE-2, of potentially a new chemical class of oral antibiotic in patients with infections of public health concern, gonorrhea and urinary tract infections.

Pipeline Watch: Phase III Readouts In Alopecia Areata, Cervical Dysplasia, Anaphylaxis

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Related Companies

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel